<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39377049</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1179-5476</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Clinical medicine insights. Case reports</Title><ISOAbbreviation>Clin Med Insights Case Rep</ISOAbbreviation></Journal><ArticleTitle>A Death for Guillain-Barrè Syndrome After Receiving a COVID-19 Vaccine: A Case Report.</ArticleTitle><Pagination><StartPage>11795476241274692</StartPage><MedlinePgn>11795476241274692</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">11795476241274692</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/11795476241274692</ELocationID><Abstract><AbstractText>The virus SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) causes COVID-19, a potentially fatal disease. The COVID-19 vaccine is indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2. We reported the case of a 66-year-old woman with a medical history of hypertension and anxious-depressive syndrome who developed Guillain Barré Syndrome (GBS) 4 weeks after receiving the COVID-19 vaccine. During the patient's hospital stay, they received cycles of high-dose intravenous immunoglobulin (IVIG) and plasmapheresis treatments.. Despite the treatment, a deterioration of respiratory function led the patient to premature mortality.</AbstractText><CopyrightInformation>© The Author(s) 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Coviello</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2298-566X</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples "Federico II", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iacovazzo</LastName><ForeName>Carmine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples "Federico II", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vargas</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples "Federico II", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Posillipo</LastName><ForeName>Concetta</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples "Federico II", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sagnelli</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples "Federico II", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diglio</LastName><ForeName>Pasquale</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples "Federico II", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cirillo</LastName><ForeName>Dario</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples "Federico II", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Servillo</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples "Federico II", Naples, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Med Insights Case Rep</MedlineTA><NlmUniqueID>101531893</NlmUniqueID><ISSNLinking>1179-5476</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">GBS</Keyword><Keyword MajorTopicYN="N">Guillan Barré syndrome</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">neurology</Keyword></KeywordList><CoiStatement>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>10</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>10</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>4</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39377049</ArticleId><ArticleId IdType="pmc">PMC11457283</ArticleId><ArticleId IdType="doi">10.1177/11795476241274692</ArticleId><ArticleId IdType="pii">10.1177_11795476241274692</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gorbalenya AE, Baker SC, Baric RS, et al.. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5:536-544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095448</ArticleId><ArticleId IdType="pubmed">32123347</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization. WHO Director-General’s Remarks at the Media Briefing on 2019-nCoV on 11 February 2020. Accessed June 22, 2020. https://www.who.int/director-general/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020</Citation></Reference><Reference><Citation>
Centers for Disease Control and Prevention (CDC). Coronavirus Disease 2019 (COVID-19). 2020. Accessed June 23, 2020. https://www.cdc.gov/covid/signs-symptoms/index.html</Citation></Reference><Reference><Citation>Mao L, Wang M, Chen S, et al.. Neurological manifestations of hospitalized patients with COVID19 in Wuhan, China: a retrospective case series study. BMJ. 2020;77:683-690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7149362</ArticleId><ArticleId IdType="pubmed">32275288</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Hu B, Hu C, et al.. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061-1069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization. The different types of COVID-19 vaccines. 12 January, 2021. Accessed 1 February, 2021. https://www.who.int/news-room/feature-stories/detail/the-race-for-a-covid-19-vaccine-explained.</Citation></Reference><Reference><Citation>Lucchese G, Flöel A. SARS-CoV-2 and Guillain-Barré syndrome: molecular mimicry with human heat shock proteins as potential pathogenic mechanism. Cell Stress Chaperones. 2020;25:731-735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7387880</ArticleId><ArticleId IdType="pubmed">32729001</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs BC, Rothbarth PH, van der Meché FGA, et al.. The spectrum of antecedent infections in Guillain-Barré syndrome. Neurology. 1998;51:1110-1115.</Citation><ArticleIdList><ArticleId IdType="pubmed">9781538</ArticleId></ArticleIdList></Reference><Reference><Citation>Compston A. Aids to the investigation of peripheral nerve injuries. Medical Research Council: Nerve Injuries Research Committee. His Majesty's Stationery Office: 1942; pp. 48 (iii) and 74 figures and 7 diagrams; with aids to the examination of the peripheral nervous system. By Michael O'Brien for the guarantors of brain. Saunders Elsevier: 2010; pp. [8] 64 and 94 figures. Brain. 2010;133:2838-2844.</Citation><ArticleIdList><ArticleId IdType="pubmed">20928945</ArticleId></ArticleIdList></Reference><Reference><Citation>Koehler PJ. The Barré and Mingazzini tests. In:Koehler PJ, Bruyn GW, Pearce JMS, eds. Neurological Eponyms. Oxford; 2000;119-126.</Citation></Reference><Reference><Citation>Fokke C, van den Berg B, Drenthen J, et al.. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014;137:33-43.</Citation><ArticleIdList><ArticleId IdType="pubmed">24163275</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig-Brangan KJ, Day MP. Update: 2017/2018 AHA BLS, ACLS, and PALS guidelines. Nursing. 2019;49:46-49.</Citation><ArticleIdList><ArticleId IdType="pubmed">30676559</ArticleId></ArticleIdList></Reference><Reference><Citation>Toscano G, Palmerini F, Ravaglia S, et al.. Guillain–Barré syndrome associated with SARS-CoV-2. N Engl J Med. 2020;382:2574-2576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7182017</ArticleId><ArticleId IdType="pubmed">32302082</ArticleId></ArticleIdList></Reference><Reference><Citation>Coen M, Jeanson G, Culebras Almeida LA, et al.. Guillain-Barré syndrome as a complication of SARS-CoV-2 infection. Brain Behav Immun. 2020;87:111-112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194931</ArticleId><ArticleId IdType="pubmed">32360440</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijdicks EF, Klein CJ. Guillain-Barré syndrome. Mayo Clin Proc. 2017;92:467-479.</Citation><ArticleIdList><ArticleId IdType="pubmed">28259232</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JE, Heo JH, Kim HO, et al.. Neurological complications during treatment of Middle East respiratory syndrome. J Clin Neurol. 2017;13:227-233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5532318</ArticleId><ArticleId IdType="pubmed">28748673</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma K, Tengsupakul S, Sanchez O, Phaltas R, Maertens P. Guillain-Barré syndrome with unilateral peripheral facial and bulbar palsy in a child: A case report. SAGE Open Med Case Rep. 2019;7:2050313X19838750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6429638</ArticleId><ArticleId IdType="pubmed">30915222</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen RT, Rastogi SC, Mullen JR, et al.. The vaccine adverse event reporting system (VAERS). Vaccine. 1994;12:542-550.</Citation><ArticleIdList><ArticleId IdType="pubmed">8036829</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann K. Spike-Induced Disturbances (SPAS*): an analysis of common suspected adverse experiences associated with Covid-19 vaccines. J Infect Dis. 2022;3:1-19.</Citation></Reference><Reference><Citation>Abara WE, Gee J, Marquez P, et al.. Reports of Guillain-Barré syndrome after COVID-19 vaccination in the United States. JAMA Netw Open. 2023;6:e2253845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9892957</ArticleId><ArticleId IdType="pubmed">36723942</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogbebor O, Seth H, Min Z, Bhanot N. Guillain-Barré syndrome following the first dose of SARS-CoV-2 vaccine: A temporal occurrence, not a causal association. IDCases. 2021;24:e01143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8086372</ArticleId><ArticleId IdType="pubmed">33968610</ArticleId></ArticleIdList></Reference><Reference><Citation>Keh RYS, Scanlon S, Datta-Nemdharry P, et al.. BPNS/ABN COVID-19 Vaccine GBS Study Group. COVID-19 vaccination and Guillain-Barré syndrome: analyses using the National Immunoglobulin Database. Brain. 2023;146:739-748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903477</ArticleId><ArticleId IdType="pubmed">35180300</ArticleId></ArticleIdList></Reference><Reference><Citation>Maramattom BV, Krishnan P, Paul R, et al.. Guillain-Barré syndrome following ChAdOx1-S/nCoV-19 vaccine. Ann Neurol. 2021;90:312-314. doi:10.1002/ana.26143</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26143</ArticleId><ArticleId IdType="pubmed">34114256</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen CM, Ramsamy S, Tarr AW, et al.. Guillain-Barré syndrome variant occurring after SARS-CoV-2 vaccination. Ann Neurol. 2021;90:315-318.</Citation><ArticleIdList><ArticleId IdType="pubmed">34114269</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Zhang J, Chu X, Xu Y, Ma F. Vaccines and the risk of Guillain-Barré syndrome. Eur J Epidemiol. 2020;35:363-370.</Citation><ArticleIdList><ArticleId IdType="pubmed">31858323</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, et al.. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Bai WZ, Hashikawa T. The neuroinvasive potential ofSARS-CoV2 may play a role in the respiratory failure of COVID- 19 patients. J Med Virol. 2020;92:552-555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228394</ArticleId><ArticleId IdType="pubmed">32104915</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedaghat Z, Karimi N. Guillain Barre syndrome associated with COVID-19 infection: a case report. J Clin Neurosci. 2020;76:233-235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7158817</ArticleId><ArticleId IdType="pubmed">32312628</ArticleId></ArticleIdList></Reference><Reference><Citation>Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillain-Barré syndrome. Drug Safety. 2009;32:309-323.</Citation><ArticleIdList><ArticleId IdType="pubmed">19388722</ArticleId></ArticleIdList></Reference><Reference><Citation>Coviello A, Vargas M, Posillipo C, Sagnelli F. et al.. A rare case of death in a patient with Guillain-Barrè syndrome after COVID-19 vaccination. Authorea. 2023.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>